NCT06905106 POlycythemia, Proteins and ErYthropoiesis
| NCT ID | NCT06905106 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Condition | Erythropoiesis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2024-09-01 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. Among these proteins, erythropoietin and interleukin-3 play a major role. Similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. The regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. Excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. The aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. These proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.
Eligibility Criteria
Inclusion Criteria: \- Persons who have given their non-opposition Patients with polycythemia: * haemoglobin value \> 16 g/dl female or \> 16.5 g/dl male * with a well-identified cause: either primary (polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation...) or secondary \[cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...) Patients control: \- persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of \< 16 g/DL for women and \< 16.5 g/DL for men Exclusion Criteria: * Person subject to a measure of legal protection (guardianship, tutorship) * Person subject to a court order * Pregnant, parturient or nursing woman * Incapable of expressing consent * Minor
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06905106 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Erythropoiesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06905106 currently recruiting?
Yes, NCT06905106 is actively recruiting participants. Contact the research team at francois.girodon@chu-dijon.fr for enrollment information.
Where is the NCT06905106 trial being conducted?
This trial is being conducted at Dijon, France.
Who is sponsoring the NCT06905106 clinical trial?
NCT06905106 is sponsored by Centre Hospitalier Universitaire Dijon. The trial plans to enroll 400 participants.